What Medaysis does

Medaysis is a privately held biotechnology firm that develops, manufactures, and distributes antibodies and detection reagents for anatomic and molecular pathology research. Its catalog spans more than 1,151 primary antibodies, 47 indirect immunofluorescence products, 22 PCR mutation detection kits, 11 ancillary reagents, and IHC detection kits, covering biomarkers for cancer (e.g., BRAF V600E, PRAME for melanoma), neuropathology (H3K27M, IDH1 R132H, ATRX), and infectious disease applications across multiple tissue types. The company's differentiated technical asset is CloDiA™ PCR, a proprietary ultra-sensitive mutation detection technology designed to measure mutant genes at lower levels than conventional PCR methods, supporting earlier cancer detection and improved prognoses.

The company operates a direct-to-customer, self-serve e-commerce model through its own storefront at medaysis.com, with no disclosed third-party distribution or reseller network. Products are priced on a per-unit, pay-as-you-go basis, with most antibodies ranging from approximately $211 to $843 depending on clone and format (standard concentrate vs. Ready-to-Use). Customers are primarily academic and commercial life science researchers in pathology and molecular biology, served by a team of fewer than 10 employees from a single headquarters in Reno, Nevada. Geographic reach is explicitly U.S.-domestic, and there is no disclosed institutional capital, parent company, partnerships, or named enterprise customers.

The business is therefore best characterized as a small, founder/owner-operated specialty reagent vendor monetizing a deep catalog of validated antibodies plus a proprietary PCR mutation-detection platform, with a self-serve commercial motion and limited evidence of partnership, channel, or geographic expansion beyond the U.S. market.

Name

Medaysis

Legal name

Medaysis

Website

https://medaysis.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Medaysis is a small U.S.-based biotech that develops and sells validated primary antibodies, IHC detection kits, and proprietary CloDiA™ PCR mutation detection reagents directly to academic and commercial life science researchers via its e-commerce storefront.

Ownership category

akta.pro rank

Product category

Anatomic and Molecular Pathology Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

akta.pro secondary industries

Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

Keywords

• Research antibodies
• IHC detection kits
• PCR mutation detection
• Anatomic pathology reagents
• Molecular pathology products

Headquarters

HQ city

Livermore

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. Antibody and Reagent Product Sales: Medaysis generates revenue through the sale of research antibodies, detection kits, and ancillary reagents for anatomic and molecular pathology. Products are sold directly through their e-commerce platform with pricing ranging from approximately $197 to $856 depending on the product type and format.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Medaysis develops, manufactures, and sells research-grade antibodies and detection reagents for anatomic and molecular pathology. Its product portfolio includes primary antibodies (1,151+ products), IHC detection kits, indirect immunofluorescence reagents, PCR mutation detection kits built on its proprietary CloDiA™ PCR technology, and ancillary reagents. Products are sold directly through the company's e-commerce website to life science researchers working in cancer, neuroscience, and infectious disease applications.

Product overview

Medaysis offers a comprehensive portfolio of antibodies and detection reagents for anatomic and molecular pathology research. The product line centers on Primary Antibodies (1,151+ products), supported by IHC Detection reagents, Indirect Immunofluorescence products (47 items), PCR Mutation Detection kits featuring the proprietary CloDiA™ PCR ultra-sensitive technology, and Ancillaries (11 products). The company focuses on cancer biomarkers, neuroscience, and infectious disease research applications, with products available for various tissue types including neuropathology, dermatopathology, gastrointestinal pathology, and hematopathology.

Differentiator

Problem solved

Functional benefit

Products and services

• Primary Antibodies Comprehensive catalog of over 1,151 primary antibodies for research use in immunohistochemistry (IHC), covering cancer biomarkers, neuroscience targets, and infectious disease markers across multiple tissue types and clonality formats (mouse monoclonal, rabbit monoclonal, rabbit polyclonal).
• IHC Detection Kits
• Indirect Immunofluorescence Reagents
• PCR Mutation Detection Kits (CloDiA™)
• Ancillaries

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Direct peers

• Cell Signaling Technology: Cell Signaling Technology is a leading US-based provider of validated antibodies and reagents for western blot, IHC, IF, flow cytometry, and other applications, with a deep catalog of cancer and neuroscience targets. It is the most direct comparable to Medaysis given overlapping applications (IHC, IF), validated antibody content, and a similar focus on research-use pathology reagents.
• Santa Cruz Biotechnology: Santa Cruz Biotechnology supplies a broad catalog of monoclonal and polyclonal antibodies for research applications including IHC, Western blot, and immunofluorescence. It competes with Medaysis for the same researcher buyer purchasing primary antibodies and detection reagents through online catalogs.
• Abcam (Danaher): Abcam is one of the largest global suppliers of research-grade antibodies and immunoassay reagents, serving academic and commercial researchers across cancer, neuroscience, and infectious disease. Overlap with Medaysis is direct in primary antibodies, IHC and ICC/IF reagents, and the same self-serve/direct-ship e-commerce buying motion used by researchers.
• Novus Biologicals (Bio-Techne): Novus Biologicals supplies a large catalog of antibodies, kits, and reagents with a strong focus on IHC and neuroscience applications. It is a direct peer given shared application areas in IHC/IF, broad SKU breadth, and similar online-purchase, researcher-buyer GTM.
• BioLegend (Bio-Techne): BioLegend provides antibodies and reagents for immunology, cancer, and neuroscience research, including flow cytometry and IHC-grade antibodies. It is comparable to Medaysis in offering validated antibodies across pathology-relevant applications and marketing directly to life science researchers.
• Atlas Antibodies: Atlas Antibodies specializes in IHC-validated antibodies, including the Triple A Polyclonals and PrecisA Monoclonals lines for human protein atlas applications, with strong neuropathology and tissue-specific content. It is a direct peer given the shared focus on IHC-grade antibodies and neuropathology biomarkers.
• Bethyl Laboratories: Bethyl Laboratories manufactures and validates polyclonal and monoclonal antibodies for academic and commercial research, with strong offerings in IHC, ChIP, and Western blot. It is comparable to Medaysis as a focused, antibody-centric tools vendor selling validated reagents directly to research customers.

Broad incumbents

• MilliporeSigma (Sigma-Aldrich): MilliporeSigma distributes a very large catalog of antibodies, reagents, and biochemicals used in IHC, IF, and molecular pathology research. It is comparable to Medaysis as a one-stop reagents supplier but operates at far greater global scale and breadth.
• Thermo Fisher Scientific (Invitrogen Antibodies): Thermo Fisher's Invitrogen antibody portfolio (including Thermo Scientific and Lab Vision IHC brands) is a broad incumbent offering primary antibodies, IHC detection, and ancillary reagents used in anatomic pathology. It competes with Medaysis across most of its catalog but at much larger scale and with global distribution.

Emerging players

• GenScript: GenScript offers custom antibody services and an off-the-shelf antibody catalog, including reagents used in cancer and infectious disease research. It overlaps with Medaysis in primary antibody products and develops proprietary research tools like the CloDiA-style platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/medaysis
• LinkedInlinkedin.com/company/medaysis-co.

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medaysis